Alphamab Oncology pioneers groundbreaking cancer treatment in China

Alphamab Oncology has commenced a phase I clinical trial (JSKN016-101) for JSKN016, a groundbreaking bispecific antibody-drug conjugate (ADC) designed to target HER3 and TROP2 in Chinese patients with advanced malignant solid tumors. TROP2, a protein present in various solid tumors, plays a role in promoting tumor growth and invasion. Notably, high levels of TROP2 are often observed in lung and breast cancers. On the other hand, HER3 overexpression has been associated with a poor prognosis in several types of cancers, including lung, breast, gastric, ovarian, and melanoma.

JSKN016 stands out as a unique ADC that simultaneously targets HER3 and TROP2, triggering apoptosis in tumor cells. The ongoing clinical trial, JSKN016-101, aims to assess the safety, pharmacokinetics, and antitumor effects of JSKN016 in Chinese patients. The study seeks to establish the maximum tolerated dose and the recommended dose for phase II trials. Developed internally using a proprietary Glycan-specific conjugation platform, JSKN016 demonstrates the ability to inhibit tumor cell growth by inducing apoptosis in cells expressing TROP2 or HER3, while also affecting neighboring antigen-negative cells.

Alphamab Oncology, a leading biopharmaceutical company, is dedicated to pioneering advanced biotherapeutics for cancer treatment. Their comprehensive approach integrates research, development, and manufacturing capabilities for biologics. The company's intellectual property portfolio encompasses protein/antibody engineering and antibody modification, with a specialization in antibody-drug conjugation and monoclonal antibodies. Notably, Envafolimab, the world's first subcutaneously injectable PD-L1 inhibitor, received approval in China in 2021, expanding access to innovative cancer therapies.

With a steadfast commitment to addressing unmet medical needs in oncology, Alphamab Oncology focuses on developing safe and cost-effective drugs to enhance cancer management and potentially improve curability.